Back to top
more

Baxter International (BAX)

(Delayed Data from NYSE)

$40.13 USD

40.13
2,013,088

-0.10 (-0.25%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $40.16 +0.03 (0.07%) 7:46 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 44% (140 out of 252)

Industry: Medical - Products

Better trading starts here.

Zacks News

Headquartered in Deerfield, IL, Baxter International Inc. (BAX) is a global medical technology company. However, the company spun off its biopharmaceuticals segment into an independent entity – Baxalta Inc. Following the spinoff, the company consists of renal and hospital products, providing items such as kidney-dialysis equipment, infusion pumps, and intravenous (IV) solutions.

Cardinal Health (CAH) Misses on Q3 Earnings, Lowers '18 View

Cardinal Health (CAH) saw a tepid Q3 owing to declining profits at the Pharmaceutical unit despite a decent performance by the Medical segment.

    Genomic Health (GHDX) Q1 Earnings Top Estimates, Margins Low

    Within Genomic Health's (GHDX) prostate cancer business, strengthened NCCN prostate cancer guidelines and additional new data increase private coverage for the Oncotype DX GPS test.

      Cardiovascular Systems (CSII) Q3 Earnings Top, Revenues Meet

      Cardiovascular Systems' (CSII) peripheral device revenues continue to gain from a consistent strength in hospital setting.

        Express Scripts (ESRX) Q1 Earnings Top, Patient Claims Fall

        Express Scripts (ESRX) witnesses year-over-year declines in patient claims in Q1, thanks to the loss of certain public sector clients.

          Pacific Biosciences (PACB) Loss Wider Than Expected in Q1

          Pacific Biosciences (PACB) Q1 earnings and revenues miss estimates; Sequel orders rise.

            Becton, Dickinson (BDX) Beats on Q2 Earnings, Lifts '18 View

            Becton, Dickinson (BDX) gains on solid segmental performance in Q2; a raised guidance for fiscal 2018 encourages.

              Hologic's (HOLX) Q2 Earnings Meet Estimates, Revenues Top

              Solid growth at Hologic's (HOLX) Breast Health and international business drives top line in Q2.

                CVS Health's (CVS) Q1 Earnings Beat Estimate, Margins Grow

                CVS Health's (CVS) year-over-year top line growth in the first quarter was primarily driven by a strong pharmacy services segment, benefiting from the upside in the specialty services.

                  AmerisourceBergen (ABC) Q2 Earnings Top, FY18 View Solid

                  AmerisourceBergen (ABC) registers strong growth in the Pharmaceutical Distribution segment and World Courier business in Q2.

                    NuVasive (NUVA) Q1 Earnings Miss Estimates, Revenues In Line

                    NuVasive (NUVA) gains on continued growth in international business along with strong case volume growth in the U.S. Hardware business in Q1.

                      Accuray (ARAY) Q3 Loss Wider Than Estimates, Revenues Top

                      Radixact System and major software overhaul drive Accuray (ARAY) in Q3.

                        Inogen (INGN) Beats Q1 Earnings Estimates, Lifts 2018 View

                        Inogen (INGN) rides on strong domestic and international sales growth in Q1; a raised guidance buoys optimism.

                          athenahealth (ATHN) Tops Earnings & Revenue Estimates in Q1

                          Revenues in Business and Services along with a strong client base boost athenahealth's (ATHN) Q1 earnings.

                            3 Reasons Why You Should Invest in Baxter International Now

                            Baxter (BAX) gains ground on strategic buyouts and a raised guidance for 2018.

                              Baxter (BAX) Beats on Q1 Earnings & Revenues, Raises '18 View

                              Solid performance in Renal Products, Medication Delivery, Pharmaceutical and Other segment boost Baxter's (BAX) Q1 results.

                                Baxter (BAX) Beats on Q1 Earnings and Revenue Estimates

                                Baxter (BAX) gains from strong domestic and international sales in Q1. A raised guidance buoys optimism.

                                  Medical Product Stock Earnings Roster for Apr 26: BAX & More

                                  Let's take a look at the factors that are likely to impact the earnings results of a few MedTech bigwigs within the broader Medical universe.

                                    Can CAG Growth for IDEXX (IDXX) Stock Return in Q1 Earnings?

                                    IDEXX (IDXX) might repeat its gain streak in CAG for Q1, earlier driven by strong double-digit growth in reference labs and consumables plus a high-single-digit rise in rapid assay sales.

                                      Can Hologic (HOLX) Diagnostics Growth Recur in Q2 Earnings?

                                      A strong Panther system and an increasing utilization of Aptima women's health assays add stimulus to Global growth within Hologic's (HOLX) molecular diagnostics.

                                        Can Hospital-Products Unit Aid Baxter (BAX) in Q1 Earnings?

                                        Positive tidings on regulatory front, expanding Hospital-Products portfolio, strategic collaborations and strong presence in the international markets are key positives for Baxter's (BAX) Q1 results.

                                          Zacks.com highlights: Baxter International, Copart, Applied Materials and Steel Dynamics

                                          Zacks.com highlights: Baxter International, Copart, Applied Materials and Steel Dynamics

                                            Tirthankar Chakraborty headshot

                                            4 Top Stocks to Buy With Superb Efficiency Level

                                            Favorable efficiency level is expected to provide impressive returns as it is believed to be positively correlated with its price performance

                                              Baxter (BAX) Banks on Portfolio Strength, Strategic Buyouts

                                              Baxter (BAX) gains on a slew of regulatory approvals and strategic collaborations.

                                                Baxter (BAX) Closes Acquisition of RECOTHROM & PREVELEAK

                                                Baxter (BAX) steadily focuses on improving its Advanced Surgery business.

                                                  Here's Why You Should Invest in Baxter International Now

                                                  Recent buyouts and positive regulatory tidings boost investors' confidence on Baxter International (BAX).